{"id":"NCT00789828","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-03","completion":"2014-10","firstPosted":"2008-11-13","resultsPosted":"2012-05-01","lastUpdate":"2016-02-03"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tuberous Sclerosis","Subependymal Giant Cell Astrocytoma"],"interventions":[{"type":"DRUG","name":"Everolimus","otherNames":["RAD001"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Everolimus","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.","primaryOutcome":{"measure":"Percentage of Participants With Best Overall Subependymal Giant Cell Astrocytomas (SEGA) Response","timeFrame":"End of core period (Week 48), and end of extension period (up to 4 years)","effectByArm":[{"arm":"Everolimus (Core Period)","deltaMin":34.6,"sd":null},{"arm":"Placebo (Core Period)","deltaMin":0,"sd":null},{"arm":"Everolimus (Extension Period)","deltaMin":57.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":24,"countries":["United States","Australia","Belgium","Canada","Germany","Italy","Netherlands","Poland","Russia","United Kingdom"]},"refs":{"pmids":["30053159","29023494","27351628","26858193","25682485","25456370","24729041","23733802","23158522"],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/portals/EXISTClinicalTrials/page.do"]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":78},"commonTop":["Stomatitis","Convulsion","Nasopharyngitis","Mouth ulceration","Pyrexia"]}}